Despite Russia’s invasion of neighboring country Ukraine, which has resulted in extensive sanctions against the aggressor from the Western world, Danish pharmaceutical firm Lundbeck will continue its activities there.
”As a pharmaceutical company, we believe we have an obligation to those patients who need our medications – these for example include people suffering from schizophrenia, depression and anxiety. This is also why drugs are usually exempted from sanctions,” Chief Commercial Officer at Lundbeck Jacob Tolstrup tells MedWatch, in a written comment.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.